Skip to main content

ICH Q7 Good manufacturing practice for active pharmaceutical ingredients (CPMP/ICH/4106/00)

 ICH Q7 is a guideline titled "Good Manufacturing Practice for Active Pharmaceutical Ingredients" (CPMP/ICH/4106/00). This guideline was developed to establish a harmonized approach to Good Manufacturing Practice (GMP) for the manufacturing of active pharmaceutical ingredients (APIs) across different regions of the world. Below is an elaboration of ICH Q7:


1. Purpose of ICH Q7:

The primary purpose of ICH Q7 is to provide a comprehensive framework for the GMP requirements specific to the manufacturing of APIs. The guideline ensures that APIs are consistently produced in a manner that meets quality, safety, and regulatory standards.

2. Scope:

ICH Q7 applies to the manufacturing of APIs intended for use in human pharmaceutical products. It covers the entire API manufacturing process, from starting materials to the final API.

3. Quality Management:

The guideline emphasizes the importance of establishing a robust quality management system to oversee API manufacturing. This includes quality risk management, quality assurance, and quality control.

4. Documentation and Record Keeping:

Comprehensive documentation and record-keeping systems are essential. Detailed records should be maintained for all stages of API manufacturing, including raw material control, production, testing, and distribution.

5. Personnel:

ICH Q7 outlines the qualifications and training requirements for personnel involved in API manufacturing. Personnel should be trained to perform their tasks effectively and safely.

6. Facilities and Equipment:

The guideline specifies requirements for facilities and equipment used in API manufacturing. Facilities should be designed, maintained, and operated to prevent contamination, cross-contamination, and mix-ups.

7. Process Validation:

Process validation is a critical component of API manufacturing. Manufacturers should validate and document the processes used to produce APIs, demonstrating their consistency and reliability.

8. Change Control:

Procedures for change control are essential to ensure that any changes in API manufacturing processes, equipment, or materials are properly evaluated, documented, and validated.

9. Starting Materials:

The guideline emphasizes the importance of selecting and controlling starting materials carefully. Manufacturers should ensure the quality and traceability of starting materials.

10. Specifications and Testing:

- Detailed specifications for APIs should be established, including criteria for identity, purity, potency, and other critical quality attributes. Appropriate analytical methods should be used to test APIs.

11. Cleaning and Cross-Contamination:

- Measures should be in place to prevent cross-contamination between different APIs or products. Cleaning procedures should be validated to ensure the removal of residues.

12. Packaging and Labeling:

- ICH Q7 includes requirements for the packaging and labeling of APIs. These processes should be carried out in a way that maintains the integrity of the API.

13. Complaints and Recalls:

- Procedures for handling complaints and initiating recalls of APIs should be established and documented.

14. Regulatory Compliance:

- Compliance with ICH Q7 is typically required by regulatory authorities when manufacturing APIs. Manufacturers must adhere to these guidelines to ensure the quality and safety of APIs.


In summary, ICH Q7 provides a comprehensive framework for GMP specific to the manufacturing of active pharmaceutical ingredients (APIs). Compliance with these guidelines is essential to ensure the quality, safety, and consistency of APIs used in pharmaceutical products. The guideline helps harmonize GMP standards globally, facilitating international trade and regulatory cooperation in the pharmaceutical industry

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

Stem-Loop PCR for siRNA

 Stem-loop PCR is a method often used for detecting and quantifying small RNAs, such as siRNA or miRNA, which are typically difficult to amplify directly due to their short lengths. The method involves the design of a stem-loop reverse transcription (RT) primer, which enhances specificity and stability of the short RNA during the RT-PCR process, allowing for sensitive detection and quantification of the siRNA. Here’s a detailed guide to how stem-loop PCR can be applied to siRNA detection: Key Steps in Stem-Loop PCR for siRNA Designing the Stem-Loop RT Primer : Structure : The stem-loop RT primer consists of a loop region flanked by complementary sequences on either side (the "stem"), which will fold back on itself to form a hairpin structure. Specific Binding Region : A short sequence complementary to the 3’ end of the siRNA is added at the end of the stem-loop primer to ensure specific binding to the siRNA target. Stabilization : The loop structure helps prevent primer-dimer...
Read more

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more